Innovations in cancer diagnostics

bioTheranostics discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer.

All tests are real time, RT-PCR based assays that are compatible with readily available, formalin-fixed paraffin embedded (FFPE) needle core biopsies, excisional biopsies, and/or surgical samples.

Molecular cancer classification that aids in the determination of tumor site of origin

CancerTYPE ID^® is a standardized, objective molecular test based on the differential expression of 92 genes that classifies tumors by matching the gene expression pattern of a patient’s tumor tissue to a database of known tumor types and histological subtypes. ^1,2

Molecular insights for breast cancer risk prognosis

Breast Cancer Index^SM predicts breast cancer recurrence risk based on proprietary molecular biomarkers, H/I and MGI.

References:
1. Ma, et al. Molecular Classification of Human Cancers Using a 92-Gene Real Time Quantitative Polymerase Chain Reaction Assay. Archives of Pathology and Laboratory Medicine, 130: 465-473, 2006.
2. Data on file.  Technical Report 021510, bioTheranostics.